Havrix 1440

Havrix 1440 is an injectable hepatitis A vaccine containing 1440 ELISA units of inactivated hepatitis A virus adsorbed on aluminium hydroxide, supplied as a 0.5 mL solution for intramuscular use. It is marketed in the European Union and prescribed for active immunization against hepatitis A infection. The vaccine is given as a single dose or as part of a two‑dose schedule, depending on the program, and is classified under ATC code J07BC01.

Havrix 1440 is indicated for the prevention of hepatitis A virus infection in individuals who have not been previously immunized. The vaccine is administered intramuscularly and can be given as a single dose or as a two‑dose series, providing long‑lasting protection. - Adults and children aged 12 months and older - Travelers to regions where hepatitis A is endemic - Outbreak control in communities or institutions - Persons with chronic liver disease - Healthcare workers at risk of exposure - Pre‑exposure prophylaxis for laboratory personnel handling hepatitis A virus

Common adverse reactions to Havrix 1440 are generally mild, occur within a few days of vaccination, and resolve without medical intervention; serious events are rare but require prompt evaluation. Common: - Pain, redness, or swelling at the injection site, usually lasting 1–3 days. - Low‑grade fever (temperature <38.5 °C) within 24 hours after injection. - Headache or mild fatigue that resolves within a few days. - Nausea or mild muscle aches reported by some recipients. Serious: - Severe allergic reaction (anaphylaxis) with hives, airway swelling, or circulatory symptoms. - Guillain‑Barré syndrome, a rare autoimmune neuropathy reported in isolated cases. - High fever (≥39 °C) persisting more than 48 hours or neurological signs.

Precautions for Havrix 1440 focus on patient history, immune status, and monitoring for adverse reactions. - Verify no previous severe allergic reaction to any hepatitis A vaccine or its components. - Defer vaccination in individuals with acute moderate or severe illness until recovery. - Use with caution in persons with known bleeding disorders; apply pressure after injection. - Pregnant women may receive the vaccine when benefits outweigh potential risks (category B). - Immunocompromised patients may have reduced antibody response; consider post‑vaccination serology. - Individuals with chronic liver disease should be vaccinated to prevent severe infection.

Havrix 1440 has limited known drug interactions, but certain agents may affect vaccine response or safety. Avoid: - Concomitant administration of immunoglobulins or blood products that may neutralize the vaccine antigen. Use with caution: - Live vaccines administered within 4 weeks before or after Havrix 1440; spacing may be required. - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish antibody production. - Antipyretics taken prophylactically may mask low‑grade fever, though they do not affect efficacy. - Chronic alcohol abuse may impair immune response to the vaccine.